معرفی
Kingston Mills is Professor of Experimental Immunology at the School of Biochemistry and Immunology, Trinity College Dublin (TCD). He serves as Academic Director of the Trinity Biomedical Sciences Institute (TBSI) and TCD Research Theme Champion for Immunology, Inflammation and Infection. Additionally, he is Co-lead on the Trinity COVID-19 Research hub. His academic journey began at TCD, followed by postdoctoral training at University College London and the National Institute for Medical Research in London, before working at NIBSC in the UK. He returned to Ireland in 1993 for an academic position at Maynooth University and was appointed to a Personal Chair at Trinity College Dublin in 2001. He previously served as Head of the School of Biochemistry and Immunology from 2008-2011.
Professor Mills' research focuses on T cells in infection and autoimmunity, with particular emphasis on respiratory immunity, vaccine development, and immunotherapeutic approaches. His work spans fundamental immunological mechanisms to translational applications, investigating how T cells respond to infections like pertussis and how these responses can be harnessed for better vaccines. His laboratory explores the balance between protective immunity and pathological inflammation, particularly in the context of respiratory infections and autoimmune conditions.
Analysis of his recent publications (2023-2024) reveals a strong focus on mucosal immunity, T cell memory, and vaccine development, with significant contributions to understanding pertussis immunity, respiratory T cell responses, and the development of next-generation vaccines. His work appears in high-impact journals including Nature, Nature Communications, and Nature Immunology, demonstrating the significance of his contributions to immunological science. His research bridges basic immunology with clinical applications, particularly in vaccine design and inflammatory disease treatment.
Professor Mills is actively involved in translational research, having co-founded three biotech companies: Opsona Therapeutics, TriMod Therapeutics, and Parvalis Tx, all focused on developing immunotherapeutics for inflammatory diseases and cancer. His research group at TBSI continues to investigate the mechanisms of T cell-mediated immunity and develop novel approaches to modulate immune responses for therapeutic benefit. His work on respiratory immunity and tissue-resident memory T cells has important implications for next-generation vaccine development against respiratory pathogens.
